Southwest Houston Research, Ltd. | Houston, TX

Research site

(Unclaimed)

Location

10850 South Wilcrest Drive, Suite 170-A, Houston, Texas, United States of America

Site insights

Top conditions

Top treatments

Semaglutide

Zirconium Silicate

Bardoxolone Methyl

VX-147

ONO-5129

Calcifediol

Iron

CTAP101

GS-4997

PF-04634817

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 27 total trials

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesit...

Enrolling

Chronic Kidney Disease

Obesity

Drug: Placebo

Drug: Cagrilintide

A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease (ALPINE 1)

Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), CKD is a condition in which the kidneys' ability to w...

Enrolling

Chronic Kidney Disease

Drug: BAY3283142

Drug: Placebo

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end s...

Active, not recruiting

End-Stage Renal Disease

End-Stage Kidney Disease

Drug: MK-2060

Drug: Placebo

Locations recently updated

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease (AMPLITUDE)

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants...

Enrolling

Proteinuric Kidney Disease

Drug: Placebo

Drug: VX-147

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular...

Enrolling

Cardiovascular Disease

Drug: Semaglutide

Drug: Cagrilintide